SCK CEN’s Post

We believe radioligand therapy can not reach patients soon enough, since it is poised to improve cancer care. 🤝 Enter our collaboration with Navigo Proteins GmbH. Our experts will examine their promising carrier molecules and pair them with terbium-161, an equally promising therapeutic radioisotope. ⚛️ The goal is to identify a suitable candidate carrier molecule within two to three years and provide all the necessary data to facilitate clinical trials. What impact does this collaboration have on development time? What are radiopharmaceuticals, and what promises does Terbium-161 hold? Read more on our website. 🔗 Find the link in the comments. #nuclear #medicine #radiopharmaceuticals